This study is designed to determine the maximum tolerated dose of the combination if irinotecan followed by docetaxel administered on a q 3 week schedule; describe toxicities of the above, evaluate the effect of irinotecan on docetaxel pharmacokinetics, and seek preliminary evidence of therapeutic activity of the combination of drugs.
Showing the most recent 10 out of 1267 publications